Prolonged survival without posttransplant immunosuppression in a large animal model

D. K. Granger, A. J. Matas, M. K. Jenkins, A. A. Moss, S. C. Chen, P. S. Almond, N. L. Ascher

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. T cells that receive T-cell antigen receptor signals but do not undergo mitosis become unresponsive to subsequent antigenic stimulation. This can be achieved by antigen presentation to T cells in the absence of critical costimulatory signals from antigen-presenting cells (APC) or in the presence of the antiproliferative drug rapamycin. In mice, peritransplant infusion of adherent APC-depleted splenocytes, which do not provide costimulatory signals to T cells in vitro, leads to T-cell unresponsiveness in vivo and specifically prolongs the survival of skin grafts that express the major histocompatibility complex (MHC) molecules expressed by the transfused cells. Our goal was to determine whether in vivo infusion of adherent APC-depleted donor peripheral blood mononuclear cells (PBMC), with or without rapamycin, induces prolonged kidney allograft survival in a large animal model. Methods. MHC homozygous inbred miniature swine (SLA(cc)) were transfused with dendritic cell-monocyte-depleted (G10-passed) PBMC (2.5 x 108 cells) from MHC disparate SLA(dd) donors, with and without three peritransfusion injections of rapamycin (0.25 mg/kg/day intramuscularly) the day before, the day of, and the day after the transfusion. SLA(cc) recipients received on SLA(dd) kidney transplant 6 days later. No posttransplant immunosuppression was given. Results. In contrast to donor-specific whole blood transfusions, which uniformly resulted in sensitization and hyperacute rejection (less than 1 day), renal allograft survival in animals that received a transfusion of G10-passed PBMC from their eventual kidney donor was similar (mean, 8.1 ± 4.6 days) to untreated controls (mean, 7.8 ± 5.0 days). Pretransplant rapamycin alone also had no effect on survival (mean, 7.7 ± 8.1 days) versus controls. The combination of G10-passed blood and peritransfusion rapamycin, however, increased survival significantly (mean, 27.3 ± 10.4 days) (p = 0.01 versus untreated recipients or recipients of only G10-passed PBMC; p = 0.03 versus recipients of rapamycin alone). Conclusions. Pretransplant transfusion with costimulator-deficient donor PBMC plus peritransfusion rapamycin treatment, but neither alone, prolongs renal allograft survival in pigs without posttransplant immunosuppression. This strategy, once optimized, may be applicable to human transplant tolerance.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalSurgery
Volume116
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Sirolimus
Immunosuppression
Animal Models
Blood Cells
Kidney
Antigen-Presenting Cells
Major Histocompatibility Complex
Allografts
T-Lymphocytes
Transplants
Miniature Swine
Survival
Antigen Presentation
Graft Survival
T-Cell Antigen Receptor
Mitosis
Blood Transfusion
Dendritic Cells
Monocytes
Swine

ASJC Scopus subject areas

  • Surgery

Cite this

Granger, D. K., Matas, A. J., Jenkins, M. K., Moss, A. A., Chen, S. C., Almond, P. S., & Ascher, N. L. (1994). Prolonged survival without posttransplant immunosuppression in a large animal model. Surgery, 116(2), 236-241.

Prolonged survival without posttransplant immunosuppression in a large animal model. / Granger, D. K.; Matas, A. J.; Jenkins, M. K.; Moss, A. A.; Chen, S. C.; Almond, P. S.; Ascher, N. L.

In: Surgery, Vol. 116, No. 2, 1994, p. 236-241.

Research output: Contribution to journalArticle

Granger, DK, Matas, AJ, Jenkins, MK, Moss, AA, Chen, SC, Almond, PS & Ascher, NL 1994, 'Prolonged survival without posttransplant immunosuppression in a large animal model', Surgery, vol. 116, no. 2, pp. 236-241.
Granger DK, Matas AJ, Jenkins MK, Moss AA, Chen SC, Almond PS et al. Prolonged survival without posttransplant immunosuppression in a large animal model. Surgery. 1994;116(2):236-241.
Granger, D. K. ; Matas, A. J. ; Jenkins, M. K. ; Moss, A. A. ; Chen, S. C. ; Almond, P. S. ; Ascher, N. L. / Prolonged survival without posttransplant immunosuppression in a large animal model. In: Surgery. 1994 ; Vol. 116, No. 2. pp. 236-241.
@article{7182ba65d5254d11b99f6c049740cb82,
title = "Prolonged survival without posttransplant immunosuppression in a large animal model",
abstract = "Background. T cells that receive T-cell antigen receptor signals but do not undergo mitosis become unresponsive to subsequent antigenic stimulation. This can be achieved by antigen presentation to T cells in the absence of critical costimulatory signals from antigen-presenting cells (APC) or in the presence of the antiproliferative drug rapamycin. In mice, peritransplant infusion of adherent APC-depleted splenocytes, which do not provide costimulatory signals to T cells in vitro, leads to T-cell unresponsiveness in vivo and specifically prolongs the survival of skin grafts that express the major histocompatibility complex (MHC) molecules expressed by the transfused cells. Our goal was to determine whether in vivo infusion of adherent APC-depleted donor peripheral blood mononuclear cells (PBMC), with or without rapamycin, induces prolonged kidney allograft survival in a large animal model. Methods. MHC homozygous inbred miniature swine (SLA(cc)) were transfused with dendritic cell-monocyte-depleted (G10-passed) PBMC (2.5 x 108 cells) from MHC disparate SLA(dd) donors, with and without three peritransfusion injections of rapamycin (0.25 mg/kg/day intramuscularly) the day before, the day of, and the day after the transfusion. SLA(cc) recipients received on SLA(dd) kidney transplant 6 days later. No posttransplant immunosuppression was given. Results. In contrast to donor-specific whole blood transfusions, which uniformly resulted in sensitization and hyperacute rejection (less than 1 day), renal allograft survival in animals that received a transfusion of G10-passed PBMC from their eventual kidney donor was similar (mean, 8.1 ± 4.6 days) to untreated controls (mean, 7.8 ± 5.0 days). Pretransplant rapamycin alone also had no effect on survival (mean, 7.7 ± 8.1 days) versus controls. The combination of G10-passed blood and peritransfusion rapamycin, however, increased survival significantly (mean, 27.3 ± 10.4 days) (p = 0.01 versus untreated recipients or recipients of only G10-passed PBMC; p = 0.03 versus recipients of rapamycin alone). Conclusions. Pretransplant transfusion with costimulator-deficient donor PBMC plus peritransfusion rapamycin treatment, but neither alone, prolongs renal allograft survival in pigs without posttransplant immunosuppression. This strategy, once optimized, may be applicable to human transplant tolerance.",
author = "Granger, {D. K.} and Matas, {A. J.} and Jenkins, {M. K.} and Moss, {A. A.} and Chen, {S. C.} and Almond, {P. S.} and Ascher, {N. L.}",
year = "1994",
language = "English (US)",
volume = "116",
pages = "236--241",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Prolonged survival without posttransplant immunosuppression in a large animal model

AU - Granger, D. K.

AU - Matas, A. J.

AU - Jenkins, M. K.

AU - Moss, A. A.

AU - Chen, S. C.

AU - Almond, P. S.

AU - Ascher, N. L.

PY - 1994

Y1 - 1994

N2 - Background. T cells that receive T-cell antigen receptor signals but do not undergo mitosis become unresponsive to subsequent antigenic stimulation. This can be achieved by antigen presentation to T cells in the absence of critical costimulatory signals from antigen-presenting cells (APC) or in the presence of the antiproliferative drug rapamycin. In mice, peritransplant infusion of adherent APC-depleted splenocytes, which do not provide costimulatory signals to T cells in vitro, leads to T-cell unresponsiveness in vivo and specifically prolongs the survival of skin grafts that express the major histocompatibility complex (MHC) molecules expressed by the transfused cells. Our goal was to determine whether in vivo infusion of adherent APC-depleted donor peripheral blood mononuclear cells (PBMC), with or without rapamycin, induces prolonged kidney allograft survival in a large animal model. Methods. MHC homozygous inbred miniature swine (SLA(cc)) were transfused with dendritic cell-monocyte-depleted (G10-passed) PBMC (2.5 x 108 cells) from MHC disparate SLA(dd) donors, with and without three peritransfusion injections of rapamycin (0.25 mg/kg/day intramuscularly) the day before, the day of, and the day after the transfusion. SLA(cc) recipients received on SLA(dd) kidney transplant 6 days later. No posttransplant immunosuppression was given. Results. In contrast to donor-specific whole blood transfusions, which uniformly resulted in sensitization and hyperacute rejection (less than 1 day), renal allograft survival in animals that received a transfusion of G10-passed PBMC from their eventual kidney donor was similar (mean, 8.1 ± 4.6 days) to untreated controls (mean, 7.8 ± 5.0 days). Pretransplant rapamycin alone also had no effect on survival (mean, 7.7 ± 8.1 days) versus controls. The combination of G10-passed blood and peritransfusion rapamycin, however, increased survival significantly (mean, 27.3 ± 10.4 days) (p = 0.01 versus untreated recipients or recipients of only G10-passed PBMC; p = 0.03 versus recipients of rapamycin alone). Conclusions. Pretransplant transfusion with costimulator-deficient donor PBMC plus peritransfusion rapamycin treatment, but neither alone, prolongs renal allograft survival in pigs without posttransplant immunosuppression. This strategy, once optimized, may be applicable to human transplant tolerance.

AB - Background. T cells that receive T-cell antigen receptor signals but do not undergo mitosis become unresponsive to subsequent antigenic stimulation. This can be achieved by antigen presentation to T cells in the absence of critical costimulatory signals from antigen-presenting cells (APC) or in the presence of the antiproliferative drug rapamycin. In mice, peritransplant infusion of adherent APC-depleted splenocytes, which do not provide costimulatory signals to T cells in vitro, leads to T-cell unresponsiveness in vivo and specifically prolongs the survival of skin grafts that express the major histocompatibility complex (MHC) molecules expressed by the transfused cells. Our goal was to determine whether in vivo infusion of adherent APC-depleted donor peripheral blood mononuclear cells (PBMC), with or without rapamycin, induces prolonged kidney allograft survival in a large animal model. Methods. MHC homozygous inbred miniature swine (SLA(cc)) were transfused with dendritic cell-monocyte-depleted (G10-passed) PBMC (2.5 x 108 cells) from MHC disparate SLA(dd) donors, with and without three peritransfusion injections of rapamycin (0.25 mg/kg/day intramuscularly) the day before, the day of, and the day after the transfusion. SLA(cc) recipients received on SLA(dd) kidney transplant 6 days later. No posttransplant immunosuppression was given. Results. In contrast to donor-specific whole blood transfusions, which uniformly resulted in sensitization and hyperacute rejection (less than 1 day), renal allograft survival in animals that received a transfusion of G10-passed PBMC from their eventual kidney donor was similar (mean, 8.1 ± 4.6 days) to untreated controls (mean, 7.8 ± 5.0 days). Pretransplant rapamycin alone also had no effect on survival (mean, 7.7 ± 8.1 days) versus controls. The combination of G10-passed blood and peritransfusion rapamycin, however, increased survival significantly (mean, 27.3 ± 10.4 days) (p = 0.01 versus untreated recipients or recipients of only G10-passed PBMC; p = 0.03 versus recipients of rapamycin alone). Conclusions. Pretransplant transfusion with costimulator-deficient donor PBMC plus peritransfusion rapamycin treatment, but neither alone, prolongs renal allograft survival in pigs without posttransplant immunosuppression. This strategy, once optimized, may be applicable to human transplant tolerance.

UR - http://www.scopus.com/inward/record.url?scp=0028088537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028088537&partnerID=8YFLogxK

M3 - Article

VL - 116

SP - 236

EP - 241

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 2

ER -